Sinopharm Group Co Ltd Class H (HK:1099)
:1099
Top Page
Sinopharm Group Co
(1099)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$23.00
▲(13.41% Upside)
Action:UpgradedDate:11/12/25
Sinopharm Group Co's overall stock score of 70 reflects a balanced outlook driven primarily by strong technical momentum, with the stock price trending above key moving averages. A reasonable valuation with a low P/E ratio and attractive dividend yield further supports the score. However, moderate financial performance, marked by thin margins and high debt levels, tempers the upside potential.
Positive Factors
Business Model Strength
Sinopharm's diversified revenue streams from distribution, manufacturing, and healthcare services provide resilience and growth potential.
Negative Factors
Profit Margin Pressure
Declining profit margins suggest rising costs or inefficiencies, which could impact long-term profitability if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Strength
Sinopharm's diversified revenue streams from distribution, manufacturing, and healthcare services provide resilience and growth potential.
Read all positive factors
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$65.28B
Dividend Yield3.75%
Average Volume (3M)4.67M
Price to Earnings (P/E)3.8
Beta (1Y)0.72
Revenue Growth-2.68%
EPS Growth-21.45%
CountryHK
Employees108,217
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.67
Shares Outstanding1,341,810,800
10 Day Avg. Volume3,523,930
30 Day Avg. Volume4,674,378
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)0.79
Price to Sales (P/S)0.11
P/FCF Ratio6.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.76Price Target Upside12.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.45
Revenue Forecast (FY)HK$597.37B
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutic...
How the Company Makes Money
Sinopharm Group generates revenue through multiple key streams. The majority of its income comes from pharmaceutical distribution, where it serves as a wholesaler and retailer for a vast array of medications and health products. Additionally, the ...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
55
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 575.82B | 584.51B | 596.57B | 552.15B | 521.05B | 456.41B |
| Gross Profit | 43.09B | 44.26B | 48.51B | 47.43B | 44.05B | 40.32B |
| EBITDA | 20.58B | 20.17B | 26.90B | 26.25B | 24.68B | 22.62B |
| Net Income | 6.80B | 7.05B | 9.05B | 8.53B | 7.76B | 7.19B |
Balance Sheet | ||||||
| Total Assets | 420.17B | 392.83B | 383.39B | 364.78B | 335.41B | 311.24B |
| Cash, Cash Equivalents and Short-Term Investments | 47.16B | 54.31B | 63.81B | 55.22B | 43.54B | 50.22B |
| Total Debt | 93.29B | 76.39B | 73.78B | 69.59B | 68.37B | 68.53B |
| Total Liabilities | 290.70B | 266.14B | 263.08B | 254.71B | 235.76B | 221.29B |
| Stockholders Equity | 80.38B | 78.88B | 74.58B | 68.07B | 61.89B | 56.36B |
Cash Flow | ||||||
| Free Cash Flow | 16.32B | 9.58B | 14.84B | 18.55B | 7.05B | 9.07B |
| Operating Cash Flow | 18.43B | 11.55B | 17.17B | 20.96B | 9.31B | 11.15B |
| Investing Cash Flow | -3.24B | -3.75B | -944.53M | -3.59B | -1.27B | -2.20B |
| Financing Cash Flow | -23.26B | -17.29B | -7.64B | -5.69B | -14.69B | 2.03B |
Sinopharm Group Co Technical Analysis
Positive
20.28
Price Trends
20.93
Negative
20.59
Positive
19.72
Positive
Market Momentum
-0.14
Negative
53.73
Neutral
71.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1099, the sentiment is Positive. The current price of 20.28 is below the 20-day moving average (MA) of 20.67, below the 50-day MA of 20.93, and above the 200-day MA of 19.72, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 53.73 is Neutral, neither overbought nor oversold. The STOCH value of 71.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1099.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$65.28B | 3.75 | 8.62% | 3.75% | -2.68% | -21.45% | |
67 Neutral | HK$65.87B | 6.62 | 7.64% | 2.67% | 2.77% | 39.24% | |
66 Neutral | HK$1.82B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$627.48M | 7.99 | 7.98% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1099
Sinopharm Group Co
20.92
4.46
27.09%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.94
2.19
22.50%
HK:1931
IVD Medical Holding Limited
1.12
-0.58
-34.12%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.81
-1.31
-18.40%
Sinopharm Group Co Corporate Events
Sinopharm Group Details Board Composition and Committee Roles
Dec 19, 2025
Sinopharm Group Co. Ltd. announced the current composition of its board of directors and the roles and functions of each director, distinguishing between non-executive, executive, and independent non-executive directors. The company also disclosed...
Sinopharm Shareholders Approve New Board Appointments at Extraordinary Meeting
Dec 19, 2025
Sinopharm Group Co. Ltd. announced that all resolutions proposed at its extraordinary general meeting held on 19 December 2025 in Shanghai were duly passed by poll, reflecting strong shareholder support for changes to its board lineup. Shareholder...
Sinopharm Group Announces EGM to Appoint New Directors
Dec 3, 2025
Sinopharm Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 19, 2025, in Shanghai, China. The meeting will address the appointment of new directors to the company’s board, including Mr. Jin Bin, Mr. Y...
Sinopharm Group Announces Board Composition and Committee Roles
Nov 6, 2025
Sinopharm Group Co. Ltd. has announced the composition of its board of directors and the roles within its five board committees. The announcement provides details on the leadership structure, which includes a mix of non-executive, executive, and i...
Sinopharm Group Announces Executive Director Changes
Nov 6, 2025
Sinopharm Group Co. Ltd. announced the resignation of Mr. Sun Jinglin as an executive director and member of the strategy and investment committee, effective immediately. Mr. Sun’s departure is amicable, with no disagreements reported. The b...
Sinopharm Group Reports Third Quarter 2025 Financial Results
Oct 30, 2025
Sinopharm Group Co. Ltd. announced its unaudited financial results for the third quarter of 2025, revealing a slight decline in revenue and net profit compared to the previous year. The company reported a 1.89% decrease in quarterly revenue and a ...
Sinopharm Group Reports Strong Financial Position for Nine Months Ending September 2025
Oct 26, 2025
Sinopharm Group Co. Ltd. has announced its unaudited financial results for the nine months ending September 30, 2025, in compliance with the PRC GAAP. The company’s consolidated financial statements reveal a total asset increase to RMB 418.3...
Sinopharm’s CNMDC Reports Mixed Financial Results for 2025
Oct 23, 2025
Sinopharm Group Co. Ltd. announced the unaudited financial results of its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the nine months ending September 30, 2025. The results showed a slight decline in revenue and operating prof...
Sinopharm Reports Steady Revenue Growth Amid Cash Flow Challenges in Q3 2025
Oct 21, 2025
Sinopharm Group Co. Ltd. announced its unaudited financial results for the third quarter of 2025, showcasing a revenue of RMB 13.75 billion, marking a 3.58% increase compared to the same period last year. The net profit attributable to shareholder...
Sinopharm Accord Reports Decline in Nine-Month Financial Performance
Oct 21, 2025
Sinopharm Group Co. Ltd. announced the preliminary financial data for its subsidiary, Sinopharm Accord, for the nine months ending September 30, 2025. The report indicates a slight decrease in total revenue and net profit compared to the previous ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.